507

Kim H[1], Chang Y S[2], Bae J H[3], Oh M M[3], Lee J G[3], Choi J B[4], Kim D K[5]
1. *Dankook University College of Medicine,* ***2.*** *Konyang University College of Medicine,* ***3.*** *Korea University College of Medicine,* ***4.*** *Ajou University College of Medicine,* ***5.*** *Dept of Urology, Eulji University College of Medicine*

EFFECTS OF ALPHA BLOCKER IN IMPROVING LOWER URINARY TRACT SYMPTOMS/BENIGN PROSTATIC HYPERPLASIA WITH PROSTATITIS

Hypothesis / aims of study
To evaluate effects of silodosin in improving Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) with prostatitis

Study design, materials and methods
A total of 49 patients with LUTS/BPH were enrolled prospectively, but 41 patients were evaluated completely. The patients were divided into 2 groups relating to the expressed prostatic secretion caused by prostate massage (group 1: more than 15 leukocytes per high power field, group 2: less than 15 leukocytes per high power field). Of 41 patients, 23 patients(group 1) had prostatitis, and 18 patients (group 2) had no inflammation. Silodosin 8 mg was administered once a day for 8 weeks. The primary efficacy criteria included, symptomatic improvement (International Prostate Symptom Score: IPSS), maximum flow rate (Qmax) and residual urine volume.

Results
In all patients, total IPSS, QoL of IPSS, voiding symptoms of IPSS and storage symptoms of IPSS were improved after treatment for 8 weeks. In group 1, there was no significant difference in the improvement of total IPSS/QoL, Qmax and PVR after treatment for 4weeks, but significant difference after treatment for 8 weeks. (Table 1) In group 2, there was significant difference in the improvement of total IPSS/QoL, Qmax and PVR after treatment for 4weeks and for 8 weeks. (Table 2)

Interpretation of results
These results suggest that in the LUTS/BPH cases with prostatitis, alpha blocker should be administered for a long time in order to obtain therapeutic effects.

Concluding message
LUTS/BPH with prostatitis was responded slowly to alpha blocker.

Table 1. Improvement of total IPSS in group 1

	base	4 weeks	8 weeks
total IPSS	20.7±7.6	17.9±7.5	14.6±7.0
p value vs base		0.228	0.001
p value vs 4 weeks			0.011

Table 2. Improvement of total IPSS in group 2

	base	4 weeks	8 weeks
total IPSS	19.3±5.4	15.2±7.7	10.6±6.2
p value vs base		0.009	0.001
p value vs 4 weeks			0.004

Disclosures
Funding: No **Clinical Trial:** Yes **Registration Number:** IRB of Dankook University Hospital **RCT:** Yes **Subjects:** HUMAN **Ethics Committee:** IRB of Dankook University Hospital **Helsinki:** Yes **Informed Consent:** Yes